Eden Biodesign has announced it has secured three new contract wins worth a total of £2.97 million.

The Liverpool-based biopharmaceutical process development and manufacturing business has put pen to paper on a new deal with an existing British client, together with contracts with brand new customers in Asia and Europe.

Eden's chief executive officer Crawford Brown said the company's growing international reputation had helped it to secure the new business.

Despite the global economic downturn, Mr Brown is confident the orders will signal the start of an exciting period for Eden.

"We are optimistic that we will be able to make further announcements of several more significant contract wins in the next few weeks and several exciting technology collaborations and partnerships in the coming months," he explained.

Earlier this year, Eden signed a deal with specialist pharmaceutical company iQur to develop a manufacturing process for its combined hepatitis A and B vaccine.